DoseVault
Metabolic Compound

Lixisenatide

Short-acting prandial GLP-1 agonist; sold as Adlyxin/Lyxumia by Sanofi.

Scientific Overview

Lixisenatide is an exendin-4 analog with a six-lysine C-terminal extension. Approved in the EU (2013, Lyxumia) and US (2016, Adlyxin) by Sanofi. Short half-life (~3h) makes it more effective for postprandial glucose than fasting glucose. ELIXA trial showed CV neutrality. Discontinued in the US in 2023 due to low uptake.

Key Research Benefits

  • ✓Strong postprandial glucose control
  • ✓Modest weight loss
  • ✓Daily dosing

Potential Side Effects

⚠Nausea
⚠Hypoglycemia (with sulfonylureas)
⚠Injection-site reaction

Research Protocols

Common Dosages

T2DM

10 -> 20 mcg
Daily SC

“Within 1h before first meal”

Note: Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Dose Calculator

🧮 Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

0.4 Units

or 0.00 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Explore Lixisenatide

Where to source

Vendors with public COAs that stock this category. Affiliate links are disclosed.

  • Limitless Life Nootropics
    FL-based research-peptide supplier with Janoshik third-party COAs and a public affiliate program at ~20%.
    COA: JanoshikAffiliate disclosed
    View vendor →
  • SwissChems
    60+ peptide catalog with Janoshik COAs; weekly affiliate payouts.
    COA: JanoshikAffiliate disclosed
    View vendor →
  • Amino Club
    EU/US-facing vendor with a 20% first-order / 10% recurring affiliate model.
    COA: Third-partyAffiliate disclosed
    View vendor →

Lixisenatide by goal

Read Lixisenatide's profile filtered through specific research goals.

Lixisenatide for Fat Loss

Molecular Profile

linear
C215H347N61O65S
44 AA Sequence

Quick Reference

Status
Research Compound
Category
Metabolic
Common Dosage
10 -> 20 mcg
Daily SC

Strictly for research purposes. Not for human consumption.

Related tools

Medical Disclaimer

Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.